Nexavar access scheme fails to sway NICE
09 September 2009
James Mills
A new draft of guidance for the national health service in England and Wales comes to the same conclusion as an earlier version – that
Bayer Schering Pharma's Nexavar (sorafenib) is not cost-effective in the treatment of advanced hepatocellular carcinoma.
Even though Bayer Schering has negotiated...
Please Login to read the full article.
09 September 2009
James Mills
Even though Bayer Schering has negotiated...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Roche pins Tarceva hope on Cancer Drugs Fund after NICE rejects appeal
- NICE "wasting a generation of anticancers" claims Pierre-Fabre in Javlor appeal
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- "Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
